ASMANEX HFA
ICS MDI
Mometasone furoate · Organon
Active Medication & Mechanism
- Mometasone furoate ICS50 mcg, 100 mcg, or 200 mcg per actuation
Synthetic corticosteroid with potent anti-inflammatory properties. Reduces airway inflammation through suppression of inflammatory cell recruitment and cytokine production.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
2/3 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 100 mcg | Patients ≥12 years (previously on bronchodilators alone or ICS) | 2 inhalations twice daily Recommended starting dose for patients previously on bronchodilators alone or ICS therapy. | 400 mcg | FDA Approved |
| 200 mcg | Patients ≥12 years (previously on oral corticosteroids) | 2 inhalations twice daily Maximum recommended dose. For patients previously on oral corticosteroids. | 800 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a bronchodilator. Not for acute bronchospasm. Use a SABA. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute relief. Use a SABA. |